Showing 7721-7730 of 7858 results for "".
- FDA Extends Deadline for Sunscreen Label Compliancehttps://practicaldermatology.com/news/20120514-fda_extends_deadline_for_sunscreen_compliance/2459802/Sunscreen manufacturers have won a small victory from the Food and Drug Administration (FDA), which has extended the deadline for compliance with new labeling back to December 2013 for some companies. The industry pushed back on the agency, which ordered changes to sunscreens last summer with an ori
- La Roche-Posay Awards Two Researchershttps://practicaldermatology.com/news/20120514-la_roche-posay_awards_two_researchers/2459803/At its seventh annual North American Foundation Research Awards, La Roche-Posay honored winners Sarina B. Elmariah, MD, PhD and Marie S. Tuttle, MD. Both researchers received a $10,000 grant to continue dermatological research and were honored at t
- Provectus Pharmaceuticals' PV-10 Phase 2 Final Data To Be Presentedhttps://practicaldermatology.com/news/20120509-provectus_pharmaceuticals_pv-10_phase_2_final_data_to_be_presented/2459806/Phase 2 final data on PV-10 for metastatic melanoma by Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) will be presented at the second European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanom
- MELA Sciences Rings in Melanoma Monday with NASDAQ Opening Bellhttps://practicaldermatology.com/news/20120507-mela_sciences_rings_in_melanoma_monday_with_nasdaq_opening_bell/2459807/MELA Sciences, Inc. (NASDAQ: MELA) is kicking off Melanoma/Skin Cancer Detection and Prevention Month by ringing the opening bell for NASDAQ Monday morning. Dr. Doris Day will ring
- Celotres Earns CE Mark Approval for Wound Healinghttps://practicaldermatology.com/news/20120504-celotres_earns_ce_mark_approval_for_wound_healing/2459808/European regulators have granted CE Mark approval for Celotres™ hydrogel scaffold from Halscion, Inc. The CE Mark approval was based on the results of a prospective, multi-center, randomized, same-patient controlled, European clinical trial evaluati
- Novartis Acquires Fougera Pharma for $1.5 Billionhttps://practicaldermatology.com/news/20120504-novartis_acquires_fougera_pharma_for_15_billion/2459809/With it's $1.5 billion acquisition of US-based Fougera Pharmaceuticals, Novartis will be the biggest maker of dermatologic generics in the country. The Fougera products will add to those of Novartis's existing generics unit Sandoz.
- PhotoMedex Completes Sale of Common Stock for $40 Millionhttps://practicaldermatology.com/news/20120430-photomedex_completes_sale_of_common_stock_for_40_million/2459812/PhotoMedex, Inc. (NasdaqGS: PHMD) expects gross proceeds of $40 million, before deducting underwriting discounts, commissions and other offering expenses, from recent sale of shares of common stock. The company closed concurrent registered offerin
- PreCision Dermatology Acquires Assets of Triax Pharmaceuticalshttps://practicaldermatology.com/news/20120430-precision_dermatology_acquires_assets_of_triax_pharmaceuticals/2459813/PreCision Dermatology has acquired the assets of Triax Pharmaceuticals LLC, a specialty pharmaceutical company with products including the mid-potency topical steroid Locoid, as well as Minocin and Tretin-X. Onset Dermatologics, the prescrip
- Enrollments Complete for Two Phase 2 ALA-PDT AK Trialshttps://practicaldermatology.com/news/20120424-enrollments_complete_for_two_phase_2_ala-pdt_ak_trials/2459815/DUSA Pharmaceuticals (NASDAQ GM: DUSA) completed patient enrollment in its Phase 2 clinical trial studying the broad area application with 1-, 2-, and 3-hour drug incubation for the treatment of actinic keratoses (AKs) of the face or scalp
- DocBookMD App Offers Secure Communication, HIPAA Compliancehttps://practicaldermatology.com/news/20120424-docbookmd_app_offers_secure_communication_hipaa_compliance/2459816/Doctors can now send X-rays and lab results back and forth, securely and with full HIPAA compliance via a new application, available for iPhone, iPad, and Android. The DocBookMD app is free for doctors who are members of their state or county medical society. All activity is run through a secure ser